BioPharm International
November 01, 2007
Features
20
11
An overall increasing proportion of future product approvals will be engineered in some way, either directly or indirectly.
November 01, 2007
Columns and Departments
20
11
The biopharmaceutical sector can look forward to a financially flush venture funding environment in 2008
November 01, 2007
Columns and Departments
20
11
The challenge is not in coming up with a list of activities to discard, but in finding a feasible way to stop doing them.
November 01, 2007
Columns and Departments
20
11
Congress postpones debate on follow-on biologics while adopting new policies likely to reshape drug development
November 01, 2007
Features
20
11
Contrary to popular belief, the out-of-specification problem started years before the Barr Decision.
November 01, 2007
Columns and Departments
20
11
A true visionary leadership is required to drive the progress of operational excellence programs in biopharmaceutical organizations
November 01, 2007
Columns and Departments
20
11
CMOs must take a proactive approach to ensure the availability of local talent
November 01, 2007
Columns and Departments
20
11
Biotechnology is definitely a hot topic in China-the country's administrators recently identified it as a "cornerstone of China's national economy by 2020." But most realize that getting there will require a better trained, specialized workforce than currently exists. The Chinese government has been pumping money into life sciences education as part of its plan to achieve a global biotechnological presence over the next 15 years.
November 01, 2007
Features
20
11
The industry needs a clear regulatory pathway for the approval of biosimilars.
November 01, 2007
Features
20
11